Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
7.34
Nov 16 • 3:59 PM ET Dollar change-0.81 Percentage change(-9.94%)
Aftermarket Close
7.34
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
493.54M
Enterprise Value
400.06M
Income
-61.48M
Sales
0.00M
Book/sh
1.36
Cash/sh
1.88
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
49
IPO
Aug 03, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
5.39
P/C
3.90
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
12.25
Current Ratio
12.25
Debt/Eq
0.03
LT Debt/Eq
0.02
Option/Short
No / Yes
EPS (ttm)
-1.03
EPS next Y
-1.06
EPS next Q
-0.28
EPS this Y
6.10%
EPS next Y
-9.73%
EPS next 5Y
-6.07%
EPS past 3/5Y
-2.38% -34.75%
Sales past 3/5Y
- -
EPS Y/Y TTM
-18.46%
Sales Y/Y TTM
-
EPS Q/Q
-23.45%
Sales Q/Q
-
Insider Own
18.62%
Insider Trans
0.00%
Inst Own
43.48%
Inst Trans
1.34%
ROA
-52.06%
ROE
-55.97%
ROIC
-47.65%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
0.91%
SMA50
-3.65%
SMA200
1.56%
Trades
Shs Outstand
67.24M
Shs Float
54.72M
52W High
9.32 -21.24%
52W Low
5.63 30.37%
Volatility
8.01% 7.53%
ATR (14)
0.56
RSI (14)
49.65
Beta
1.21
Rel Volume
1.03
Avg Volume
682.62K
Volume
705,531
Perf Week
-1.08%
Perf Month
10.88%
Perf Quarter
7.15%
Perf Half Y
9.72%
Perf YTD
-2.78%
Perf Year
11.89%
Perf 3Y
85.44%
Perf 5Y
219.13%
Perf 10Y
-
Prev Close
8.15
Price
7.34
Change %
-9.94%
Consensus
Strong Buy
Avg. Price Target
$16.66
Implied Upside
+127.0%
Analysts10incl. previous ratings
Rating Distribution10 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 09, 2026Initiated
RY logoRRBC Capital Mkts
Outperform$14+90.7%
Sep 24, 2026Initiated
WWedbush
Outperform$17+131.6%
Jun 26, 2026Initiated
OPY logoOOppenheimer
Outperform$17+131.6%
May 21, 2026Initiated
SF logoSStifel
Buy$25+240.6%
Mar 23, 2026Initiated
WWilliam Blair
Outperform
Jul 24, 2025Initiated
CCantor Fitzgerald
Overweight$11+49.9%
Jun 26, 2025Initiated
HH.C. Wainwright
Buy$12+63.5%
Jun 16, 2025Initiated
CCanaccord Genuity
Speculative Buy
Feb 21, 2025Initiated
CCraig Hallum
Buy$12+63.5%
Nov 14, 2024Initiated
RRodman & Renshaw
Buy$9+22.6%
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. It delivers drugs into body compartments, such as the joint without any of the common issues with body compartment injections, such as systemic exposure. The firm focuses on arthritis, diabetic macular edema, and chronic pain programs. The company was founded by James A. Helliwell, John Salvatore Montalbano and Amanda Malone on May 12, 2011 and is headquartered in Victoria, Canada.
M.D.Dr. James A. Helliwell FRCPC
M.B.A.Mr. Alexander John Rothwell Eng.
M.Sc.Mr. Paul Anthony Brennan B.Sc.
CCPMs. Wajida Leclerc B.A.
Executive VP of R&DMr. Alex Therien